Bruker Corporation reported third-quarter 2025 revenues of $860.5 million, a slight decrease year-over-year but showing sequential improvement in organic bookings, particularly in the biopharma sector.

• Organic bookings grew mid-single digits, with high teen percentage growth in government and academic markets, signaling a potential turnaround.
• Third-quarter non-GAAP operating margin improved sequentially to 12.3%, from 9.0% in Q2 2025, despite lower year-over-year revenue absorption.
• Currency fluctuations contributed a 2.9% tailwind; however, organic revenue declined 4.5% year-over-year, indicating ongoing challenges in the scientific instruments segment.
• Cost savings initiatives are on track to meet goals of $100 million to $120 million, expected to bolster margins and EPS growth in 2026.